Research tracker · FAQ
CJC-1295: frequently asked questions, answered from the record
Direct answers on safety, side effects, regulatory status, and the testosterone questions — each tagged to a study where a number is involved.
What CJC-1295 is and how it acts
These cover the basics — definition, mechanism, classification, and the forms. Where a number appears, it is tagged to the study that measured it; where the honest answer is that the data do not exist, the answer says so. This page is the full index of the questions readers ask; the topic pages carry the same answers in context.
Dosage, handling, and the ipamorelin pairing
Every answer here reports research parameters or handling notes from the published record. None is a recommendation, a protocol, or a dose to take — there is no approved human dose for CJC-1295.
What does the literature note about CJC-1295 side effects?
CJC-1295 is an unapproved research chemical, and the safety answers below come from a limited human record plus the known biology of the GH/IGF-1 axis. The reported concerns are inferred from GH-axis biology and IGF-1 epidemiology, not measured in large dedicated CJC-1295 safety trials, because no such trials exist.
The testosterone questions
A recurring cluster of searches asks whether CJC-1295 changes testosterone. The short answer across all of them: it acts on the growth-hormone axis, not the gonadal axis, and the published record reports no direct testosterone effect either way.